Our previous analysis established that following seven consecutive days of treatment with the KRAS-G12C inhibitor MRTX1257, although 3LL tumor growth was inhibited, tumors did not regress, indicating that KRAS-G12C inhibitors alone are not sufficient to cause tumor regression in this model (9). This evidence concerns the gene KRAS and neoplasm.